Cognition Therapeutics Inc (CGTX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cognition Therapeutics inc   (NASDAQ: CGTX)


Cognition Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Cognition Therapeutics Inc 's ROA in the second quarter of 2026?
Cognition Therapeutics Inc recorded a cumulative net loss of $-17 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -40.44%.

However, within the Healthcare sector Cognition Therapeutics inc achieved the highest return on assets. While the total ranking for ROA unchanged, relative to the first quarter of 2026 at no. .

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 102.34 % 55.67 % 61.7 % 59.2 % -43.1 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -17 -20 -23 -28 -33
Return On Assets (TTM) -40.44 % -53.55 % -70.42 % -97.29 % -133.24 %
CGTX's Total Ranking # # # # #
Total Assets (TTM) in million 39 36 48 43 19
Seq. Total Assets Change 8.37 % -25.36 % 11.71 % 123.91 % -16.62 %
Seq. Net Income Change - - - - -

CGTX's 5 Years Annual ROA >> Back to CGTX Management Effectiveness >> Compare CGTX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Assets Statistics
High Average Low
0 %
0 %
0 %
 



  News about Cognition Therapeutics inc Return on Assets ROA

Advancing Hope Cognition Therapeutics Champions Lewy Body Dementia Awareness While Pioneering Promising Treatments

As September marks Lewy Body Dementia Awareness Month, Cognition Therapeutics Inc. is taking significant steps to elevate public understanding of this often-overlooked neurodegenerative disorder, while simultaneously advancing its commitment to the development of effective treatments. As the second most common form of dementia, Lewy Body Dementia (LBD) presents unique challenges not only to those afflicted but also to their caregivers and the broader healthcare community. Cognition Therapeutics recognizes the urgent need for innovative therapy options, particularly as the global demographic shifts reveal burgeoning numbers of individuals at risk.Cognition Therapeutics is at the forefront of this critical fight against LBD. The company s lead candidate, CT1812, is currently being evaluated in the Phase 2 SHIMMER clinical trial a crucial step towards determining its efficacy in treating dementia with Lewy bodies. With data readout anticipated in the fourth quarter of 2024, the SHIMMER trial represents a beacon of hope for patients and their families who are grappling with the complexities of LBD. The trial aims to assess not only the safety and tolerability of CT1812 but also its potential to enhance cognition and daily functioning for those affected by this debilitating condition.



Financial Statements
Cognition Therapeutics Inc 's Assets $ 39 million CGTX's Balance sheet
Cognition Therapeutics Inc 's Income $ -4 million Quarterly CGTX's Income Statement
CGTX's Income by Division See CGTX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 61.7 % -13.82 % -31.57 % -14.73 % -
Total Assets in million 48 30 35 50 59
Y / Y Net Income Change - - - - -
Net Income in million -23 -34 -26 -21 -12
Annual Return On Assets -48.85 % -114.24 % -74.73 % -42.43 % -19.81 %

CGTX's 5 Years Annual ROA >> Back to CGTX Management Effectiveness >> Compare CGTX ROA to its Competitors



More Return On Assets Ratios
CGTX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CGTX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CGTX's Competitors
Subscribers only: Roa for Cognition Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CGTX's Customers

You may also want to know
CGTX's Roi CGTX's Inventory Turnover Ratio CGTX's Growth Rates CGTX's Dividend Comparisons
CGTX's Profitability Ratios CGTX's Asset Turnover Ratio CGTX's Dividend Growth
CGTX's Roe CGTX's Valuation Ratios CGTX's Financial Strength Ratios CGTX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-08T17:05:34+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.